Related Experiment Videos
The preclinical toxicological evaluation of sumatriptan
K Owen1, K Hartley, M L Tucker
1Glaxo Research and Development Ltd, Park Road, Ware, Hertfordshire, UK.
Human & Experimental Toxicology
|December 1, 1995
Summary
Extensive toxicological studies show that sumatriptan, a migraine medication, is safe for oral and subcutaneous use. High doses were well-tolerated in animals, with no genotoxic, oncogenic, or teratogenic effects observed.
Area of Science:
- Pharmacology
- Toxicology
- Drug Safety
Background:
- Sumatriptan is a selective 5-HT1 receptor agonist used for migraine treatment.
- A comprehensive toxicological evaluation is essential for drug safety assessment.
Purpose of the Study:
- To evaluate the local and systemic tolerance of sumatriptan.
- To assess the reproductive, genotoxic, and oncogenic potential of sumatriptan.
- To provide safety assurance for sumatriptan's therapeutic use.
Main Methods:
- High-dose oral, subcutaneous, and intravenous administration of sumatriptan in rodents and dogs.
- Evaluation of systemic and local tolerance, reproductive parameters, and genotoxicity/oncogenicity.
- Behavioral observations, clinical pathology, and histopathology.
Main Results:
- Sumatriptan was well-tolerated at high doses across administration routes.
- Transient central nervous system effects were observed, more pronounced in dogs.
- No genotoxic, oncogenic, or teratogenic effects were found; embryotoxicity occurred only at maternally toxic doses.
Conclusions:
- Sumatriptan demonstrates a good safety profile for oral and subcutaneous administration.
- The toxicological program supports the safe use of sumatriptan in migraine therapy.
- No significant safety concerns were identified in extensive animal studies.